Erythropoietin reduces anemia and transfusions

Dunphy, Frank; Harrison, Bruce R.; Dunleavy, Teresa L.; Rodriguez, Jack J.; Hilton, Jack G.; Boyd, James H.

doi:10.1002/(sici)1097-0142(19991001)86:7<1362::aid-cncr36>3.0.co;2-t

Cited by 47 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer patient care RhEPO is regarded as an agent which can decrease the need for blood transfusions and improve the patients' quality of life [24,25,26,27]. This improvement in quality of life is supposed to be a direct consequence of the raised hemoglobin concentration.…”

Section: Discussionmentioning

confidence: 99%

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Halteren¹,

Bongaerts²,

Verhagen³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Halteren¹,

Bongaerts²,

Verhagen³

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Our first, literature-based meta-analysis evaluated 19 trials including 2,805 patients for overall survival [12]. We obtained overall survival data either from the literature [29,[43][44][45] or from study investigators [46][47][48][49][50][51][52][53][54][55][56][57][58][59][60]. We found a HR of 0.81 (95% CI 0.67-0.99, figs 1 and 2), favouring ESAs.…”

Section: Resultsmentioning

confidence: 99%

“…For the 19 studies which had already been included in the first review [12] we compared the results reported in the different sources. For the six studies [43,45,49,54,55,58], no additional data were retrieved for the IPD review because the studies were too small for inclusion [27,28]. The results for these six studies [43,45,49,54,55,58] are therefore identical in the first review and the hypothetical meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…For the six studies [43,45,49,54,55,58], no additional data were retrieved for the IPD review because the studies were too small for inclusion [27,28]. The results for these six studies [43,45,49,54,55,58] are therefore identical in the first review and the hypothetical meta-analysis. For 13 studies [29, 44, 46-48, 50-53, 56, 57, 59, 60] we had results stemming from the first review [12] and the IPD meta-analysis [28].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents

Tonia¹,

Schwarzer²,

Bohlius³

2013

Swiss Med Wkly

View full text Add to dashboard Cite

Reporting and publication bias is a well-known problem in meta-analysis and healthcare research. In 2002 we conducted a meta-analysis on the effects of erythropoiesis-stimulating agents (ESAs) on overall survival in cancer patients, which suggested some evidence for improved survival in patients receiving ESAs compared with controls. However, a meta-analysis of individual patient data conducted several years later showed the opposite of our first meta-analysis, that is, evidence for increased on-study mortality and reduced overall survival in cancer patients receiving ESAs. We aimed to determine whether the results of our first meta-analysis could have been affected by publication and reporting biases and, if so, whether timely access to clinical study reports and individual patient data could have prevented this. We conducted a hypothetical meta-analysis for overall survival including all studies and study data that could have been available in 2002, at the time when we conducted our first meta-analysis. Compared with our original meta-analysis, which suggested an overall survival benefit for cancer patients receiving ESAs [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.67‒0.99], our hypothetical meta-analysis based on the results of all studies conducted at the time of the first analysis did not show evidence for a beneficial effect of ESAs on overall survival (HR 0.97, 95% CI 0.83‒1.12). Thus we have to conclude that our first meta-analysis showed misleading overall survival benefits due to publication and reporting biases, which could have been prevented by timely access to clinical study reports and individual patient data. Unrestricted access to clinical study protocols including amendments, clinical study reports and individual patient data is needed to ensure timely detection of both beneficial and harmful effects of healthcare interventions.

show abstract

“…Owing to the hormonal activity of EPO with respect to the stimulation of the red blood cell production, the glycoprotein has been used for the treatment of anaemia [11][12][13][14][15] ever since its first recombinant expression in 1985 [16]. EPO is also known as a performance-enhancing substance in endurance sports [17][18][19], being prohibited by the World Anti-Doping Agency since 1990 [20].…”

Section: Introductionmentioning

confidence: 99%

Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS

2012

View full text Add to dashboard Cite

Erythropoietin reduces anemia and transfusions

Cited by 47 publications

References 20 publications

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model

Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents

Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS

Contact Info

Product

Resources

About